Once a Covid-19 vaccine is approved, it will face the logistical challenges of fragile supply chains in some parts of the world, coupled with potential shortages of even basic equipment such as syringes, warns Senior Research Fellow Oksana Pyzik (Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø School of Pharmacy).